败血症驱动的代谢重编程塑造了癌症免疫疗法的有效性,转移潜力和药物敏感性
Leyi Wang1, Changdong Wu1, Ming Hou1
1People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Frontiers in immunology
|September 17, 2025
概括
败血症和癌症有着复杂的关系,败血症改变了新陈代谢,阻碍了癌症免疫治疗,促进了转移. 针对新陈代谢,免疫和微生物组的综合治疗对于更好的患者结果至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢研究研究 代谢研究
背景情况:
- 败血症和癌症表现出复杂的双向相互作用,显著影响患者的预后.
- 代谢重编程是一个关键因素,它调解了败血症和癌症之间的相互作用.
- 败血症引起的免疫失调和代谢变化促进免疫抑制,瘤进展,转移和免疫疗法耐药性.
研究的目的:
- 探索败血症驱动的代谢重编程对癌症免疫疗法和转移的影响.
- 为未来为毒和癌症患者开发综合治疗策略提供基础.
- 通过生物标志物识别来突出个性化护理的需要.
主要方法:
- 关于败血症与癌症相互作用,代谢重编程和免疫治疗的当前文献的综述.
- 在败血症的背景下分析分子洞察力,免疫疗法疗效和药物敏感性.
- 探索整合代谢干预和抗微生物方法的潜在治疗策略.
主要成果:
- 败血症通过促进免疫抑制,瘤生长,转移和通过代谢重编程对免疫治疗的抵抗,显著影响癌症的进展.
- 癌症患者,特别是那些接受免疫抑制疗法的人,患败血症的风险更高,导致治疗复杂,结果更差.
- 综合治疗方法至关重要,结合免疫疗法,代谢干预和抗菌战略.
结论:
- 败血症驱动的代谢重编程极大地影响了癌症免疫疗法和转移.
- 综合治疗策略是必要的,以解决败血症,癌症代谢和免疫之间的复杂相互作用.
- 未来的研究应该专注于开发精确的疗法,调节新陈代谢,免疫力和微生物群,以改善患者的治疗结果.
相关概念视频
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


